Margolis AM, Heverling H, Pham PA, Stolbach A
Compound: Exenatide Class: GLP-1 receptor pathway research peptide Strength Per Spray: 50MCG Serving Strength: 100MCG Sprays Per Serving: 2 sprays Total Spray Count: Approximately 100 sprays Total Servings: Approximately 50 servings Total Volume: 10ML Total Exenatide Content: 5MG Format: Pre-made cGMP aerosol peptide research spray Formula Type: Finished pre-formulated research spray Research Focus: GLP-1 receptor signaling, incretin pathway research, glucose-response biology, metabolic regulation, beta-cell signaling, and energy-balance pathway studies
Most patients tolerate NAD injections very well
Soranna D, Scotti L, Zambon A, et al
Current evidence suggests that inflammation contributes to EDC through upregulation of central inflammatory cytokines, overactivation of microglia and astrocytes, and hyperactivation of the HPA axis, leading to neurotransmitter imbalance, impaired synaptic plasticity, increased pyroptosis, and OSpositioning EDC as a prototypical inflammation-driven and stress-driven neuropsychiatric comorbidity (Xu et al., 2018
PMCID: PMC8942009